Riskpilot← Back to searchSign inGet full accessKRINGELUM SCIENCES ApS
APSActiveCVR 35675779Skansevej 71Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 2014— employees
Revenue 2024
DKK 118K
+125% vs 2023
EBITDA margin
95.2%
+159% vs 2023
Equity ratio
65.0%
Financial strength
Net profit 2024
DKK 88K
+141% vs 2023
| Revenue | DKK 118K | +125% |
| EBITDA | DKK 112K | +159% |
| Net profit | DKK 88K | +141% |
| Total assets | DKK 250K | +87% |
| Equity | DKK 163K | +32% |
| Employees | — | — |
Legal name
KRINGELUM SCIENCES ApS
CVR number
35675779
Legal form
Anpartsselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
10. februar 2014
Share capital
DKK 40.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse eller af en direktør i forening med et bestyrelsesmedlem.
Company purpose
Selskabets formål er at drive virksomhed med at adminstrere ejerandele i videns baseret virksomheder og hermed forbundet virksomhed.
Address
Skansevej 71
Phone
+4527125173
Email
jens@kringelum.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 46 | 41 | 324 | 123 | 39 | 0 | 0 | 0 | 53 | 118 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 10 | 44 | 29 | 318 | 118 | 31 | -4 | -5 | -10 | 43 | 112 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 10 | 44 | 29 | 318 | 118 | 31 | -4 | -5 | -10 | 43 | 112 |
| Net financials | 0 | 6 | 4 | 3 | 6 | 1 | 6 | 8 | 20 | 3 | 0 |
| Profit before tax | 10 | 51 | 33 | 321 | 124 | 32 | 1 | 3 | 9 | 47 | 112 |
| Tax | 2 | 10 | 6 | 70 | 26 | 7 | 0 | 1 | -0 | 10 | 25 |
| Net profit | 8 | 40 | 26 | 251 | 98 | 25 | 1 | 2 | 9 | 36 | 88 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 12 | 59 | 82 | 376 | 414 | 302 | 240 | 184 | 213 | 134 | 250 |
| Equity | 9 | 49 | 75 | 299 | 332 | 295 | 237 | 184 | 211 | 123 | 163 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 | 10 | 7 | 77 | 82 | 7 | 4 | 1 | 2 | 10 | 88 |
| Total debt | 2 | 10 | 7 | 77 | 82 | 7 | 4 | 1 | 2 | 10 | 88 |
EBITDA margin
95.2%
This company
15.8%
Market median
+503% vs market
20142024
Equity ratio
65.0%
This company
38.2%
Market median
+70% vs market
20142024
Return on equity
53.9%
This company
18.4%
Market median
+193% vs market
20142024
Net profit margin
74.3%
This company
8.1%
Market median
+817% vs market
20142024
Asset turnover
0.47×
This company
1.12×
Market median
-58% vs market
20142024
Debt / equity
0.54×
This company
0.62×
Market median
+13% vs market
20142024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-02-18 – 2014-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
KRINGELUM SCIENCES ApS (this company)
SeeQ Diagnostics ApSBoard members of KRINGELUM SCIENCES ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|